Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency

Ki Hyang Kim, Ho Young Kim, Hye Ryun Kim, Jong Mu Sun, Ho Yeong Lim, Hyo Jin Lee, Suee Lee, Woo Kyun Bae, Sun Young Rha

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)


Background Patients with metastatic renal cell carcinoma (mRCC) with renal insufficiency are generally excluded from clinical trials, despite their increasing numbers. Thus, we evaluated the efficacy and toxicity of sunitinib in such patients. Patients and methods Korean patients with mRCC with renal insufficiency who had received sunitinib as first-line treatment between January 2008 and May 2012 were included. Patient characteristics, clinical outcomes and toxicities were evaluated. Overall survival (OS) and progression-free survival (PFS) were determined according to the degree of renal impairment. Results The median age of the 34 patients evaluated was 66 years, 90% had an Eastern Cooperative Oncology Group performance status of 0 or 1 and the median glomerular filtration rate was 46.5 mL min-1·1.73 m -2 (range, 21.1-59.5). The starting sunitinib dose was 37.5 and 50 mg for 12 and 22 patients, respectively. A 4-weeks-on-2-weeks-off regimen was followed for 31 patients; a 2-weeks-on-2-weeks-off regimen, for one patient; and a daily regimen, for two patients. The best response was partial response in eight patients and stable disease in 12. Median OS and PFS times were 26.3 months (95% confidence interval [CI]: 17.1-35.3) and 12.2 months (95% CI: 10.2-13.2), respectively. Common non-haematologic adverse events (AEs) were stomatitis, rash, general oedema and fatigue. The most common AEs of ≥grade 3 severity were fatigue, neutropenia and thrombocytopenia. Conclusions In patients with mRCC with renal insufficiency, sunitinib was efficacious and did not cause increased toxicity. Thus, clinicians should not hesitate to treat patients with mRCC with renal insufficiency with sunitinib.

Original languageEnglish
Pages (from-to)746-752
Number of pages7
JournalEuropean Journal of Cancer
Issue number4
Publication statusPublished - 2014 Mar

Bibliographical note

Funding Information:
This work was supported by the 2011 Inje University research grant and the Public Welfare & Safety Research Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT & Future Planning ( 2010-0020841 ).

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency'. Together they form a unique fingerprint.

Cite this